Back to School: How biopharma can reboot drug development. Access exclusive analysis here

FDA wants amended approval process

FDA published in the Federal Register a proposed rule to amend to the approval and notification process for NDAs and ANDAs. In the 58-page document, the agency

Read the full 277 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE